Hungary

BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)... 2012-04-05

BMI View: Drugmakers operating in Hungary should be concerned by the latest comments from an important member of Hungary's Fidesz party that indicate the government may be preparing... 2012-02-29

BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients... 2011-11-02

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12

BMI View: Small changes to Hungary's 2012 budget plan are moderately good news for drugmakers. However, longer-term savings targets have been maintained and the impact of legislated... 2011-10-11

BMI View: The biosimilar licencing deals signed between Gedeon Richter and Stada are mutually beneficial, lowering the risks and costs associated with drug development and adding to... 2011-08-31

BMI View: While 2012 is set to be an unusually difficult year for drugmakers in Central Europe, we maintain our view that the long-term growth potential of this region is favourable,... 2011-08-25

BMI View: We now believe that Hungarian generic drugmaker Gedeon Richter's stock is undervalued. The company's share price has underperformed as investors have been wary of domestic... 2011-05-27

BMI View: We believe that the Hungarian government's aim to decrease pharmaceutical subsidies by increasing the burden on drugmakers, and attempting to avoid any form of increased patient... 2011-05-24

BMI View: We have lowered our projections of Hungary's pharmaceutical market in response to the government's structural reform programme to control prices and public expenditure on... 2011-03-07